

LETTERS

Comment on Neuronal networks in epileptic encephalopathies with CSWS

To the Editors:

I read with great interest the work of Japaridze et al¹ in *Epilepsia*.

They wrote: “An activation of spike and wave activity during slow sleep provides a clear argument for involvement of the thalamocortical network. Synchronization of epileptiform spikes and slow oscillation during slow sleep may involve mechanism similar to one described by Steriade and colleagues . . .”

Our question is: What is the nature of the discharges? Are they really “generalized spike-and-wave” or regional discharges?

The first publications about ESES spoke explicitly about generalized spike-and-wave discharges. Not only the electromorphology was considered to be “spike-and-wave” but the recent interpretations about the pathomechanism of the discharges also went back to the classical generalized spike wave pattern, similarly to the present interpretation of Japaridze et al.^{2,3} However, focal/regional discharges were frequently reported.^{3–6} Beaumanoir⁷ already pointed out that “during ESES, the interictal EEG abnormalities during wakefulness are similar to those before ESES, but are usually more marked.”

The last overview of the Tassinari group⁸ is summarized as follows: “The EEG during wakefulness shows usually focal, or multifocal, slow spikes with frequent associated diffuse slow spikes and waves. In a proportion of cases, the EEG can show features similar to what one observes in “idiopathic” focal (“Rolandic,” frontal or, less frequently, parietooccipital) epilepsies or syndromes. Figure 9 of Tassinari et al.⁸ shows a clear-cut map of a focal/regional parietotemporal discharge, nothing to do with the classical bilateral spike-wave pattern.

Thus doubts can be raised about the existence of a unitary mechanism of ESES because discharges show heterogenic forms; they are bilateral spike-waves but in the majority of cases are focal/regional discharges like in Rolandic or in other focal idiopathic childhood epilepsies. The literature is astonishingly poor in studies that analyze the potential fields of the ESES discharges. In our study⁹ from the 33 (18 lesional and 15 nonlesional) children with ESES, only 3 (<10%) (two nonlesional and one lesional) showed the classical generalized spike and

wave field. It was characterized by bilateral more or less symmetric distribution, with a uniform dipole (anterior negative and posterior positive half-fields) without unihemispherical phase reversal. All the other patients regardless of lesional or nonlesional etiology showed unihemispherical phase reversals of their discharges with anterior, medial, and posterior localization along the Sylvian fissure as an axis, almost equally distributed. Thus we can say that in our material showing lesional and nonlesional cases in 54.5:46.5% rate, the overwhelming majority had spike fields similar to what we observe in focal/regional childhood idiopathic hyperexcitability syndromes. This finding enlightens our lack of detailed knowledge about the nature of the discharges, and raises the possibility that the majority of the discharges might reflect a more circumscribed regional network and that their electromorphology, spatial distribution, and functional properties are not similar to the classical generalized spike-wave pattern.

DISCLOSURE

I have no conflicts of interest to disclose. I confirm that I have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Péter Halász
halasz35@gmail.com

*National Institute of Clinical Neuroscience, Budapest,
Hungary*

REFERENCES

1. Japaridze N, Muthuraman M, Dierck C, von Spiczak S, Boor R, Mideksa KG, Anwar RA, Deuschl G, Stephani U and Siniatchkin M. Neuronal networks in epileptic encephalopathies with CSWS. *Epilepsia* 2016;57:1245–1255.
2. Loddenkemper T, Sanchez Fernandez J, Peters JM. Continuous spike and waves during sleep and electrical status epilepticus in sleep. *J Clin Neurophysiol* 2011;28:154–164.
3. Sánchez Fernández I, Loddenkemper T, Peters JM, et al. Electrical status epilepticus in sleep: clinical presentation and pathophysiology. *Pediatr Neurol* 2012;47:390–410.
4. Saltik SI, Uluduz D, Cokar O, et al. A clinical and EEG study on idiopathic partial epilepsies with evolution into ESES spectrum disorders. *Epilepsia* 2005;46:524–533.
5. Van Hirtum-Das M, Licht EA, Koh S, et al. Children with ESES: variability in the syndrome. *Epilepsy Res* 2006;70(Suppl. 1):248–258.
6. Kramer U, Sagi L, Goldberg-Stern H, et al. Clinical spectrum and medical treatment of children with electrical status epilepticus in sleep (ESES). *Epilepsia* 2009;50:1517–1524.
7. Beaumanoir A. *Continuous spike-waves during slow wave sleep. Electrical status epilepticus during slow wave sleep*. London: John Libbey; 1995:217–223.
8. Tassinari CA, Cantaplupo G, DallaBernardina B. Encephalopathy related to status epilepticus during slow sleep (ESES) including Lan-

dau-Kleffner syndrome. In Bureau M, et al. (Eds) *Epileptic syndromes in infancy and adolescence*. 5th Ed. Montrouge, France: John Libbey Eurotext Ltd., 2012:255–275

9. Hegyi M, Siegler Zs, Fogarasi A, et al. Age dependent features of lesional and non-lesional patients with electrical status epilepticus in slow sleep. *Ideggyogy Sz* 2014;69:21–28.

In response: Neuronal networks in epileptic encephalopathies with CSWS

To the Editors:

In his commentary of our article,¹ Prof. Péter Halász points out an important issue of the nature of epileptiform discharges during electrical status epilepticus in sleep (ESES) and offers a thorough review of the topic. Furthermore, due to the diversity of the epileptiform discharges, which are mainly focal/regional discharges or bilateral spike-waves,² he raises doubt about the existence of unitary mechanism of ESES and suggests that most of the discharges might reflect a more confined regional network.³

A better understanding of the morphology and localization of the epileptiform discharges during ESES is an important issue. However, as noted by Dr. Halász, there are only few studies analyzing the potential fields of ESES discharges.⁴ We concur with Dr. Halász that heterogeneity of discharges can be responsible for differences in clinical presentations of patients with ESES, and can be used as an argument against the existence of the unitary mechanisms of ESES discharges.

Similar to the observations of previous authors,^{2,3,5–7} we observed that most our patients exhibited regional discharges with mainly centrottemporal or parietooccipital predominance. However, we did not focus on detailed and systematic analyses of the morphology and localization of discharges. The aim of our previous study was to investigate the unifying mechanisms that generate background oscillations, as opposed to epileptiform discharges, of patients with ESES. As such, localization of the discharges or differences in seizure forms were not taken into account.

We would argue that the delta frequency oscillations observed during the acute phase of continuous spikes and waves during sleep (CSWS) represent a unified network signal that is significantly associated with the coherent sources we observed.⁸ Furthermore, we believe that the complexity of the observed network may explain the diversity of neurophysiologic deficits characteristic of this condition.

The high temporal resolution that electroencephalography (EEG) provides, in conjunction with advancements in source analysis methods, allowed a description of the hierarchical association. This enabled us to identify the thalamus, together with the mesial temporal and parietal regions, as the epicenter of the network. Based on the

results obtained from the directionality analyses, we concluded that the posteromedial cortical region is merely a precipitator, which acts on the thalamocortical network and facilitates the development of epileptiform discharges.

We strongly agree that the detailed and systematic analyses of the morphology of spike and wave discharges, in addition to studies focused on networks underlying epileptiform discharges in ESES, are topics of great interest, both of which we hope will be the focus of future research pursuits.

ACKNOWLEDGMENTS

We are grateful to the patients, parents, and colleagues who contributed to the study. The support for the authors from the German Research Council (Deutsche Forschungsgemeinschaft, DFG: SFB 855, D2, and D3, and PAK902) and European Commission, Project FP7 DESIRE is gratefully acknowledged.

DISCLOSURE

None of the authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Natia Japaridze*

n.japaridze@pedneuro.uni-kiel.de

Muthuraman Muthuraman^{†‡}

Carina Dierck*

Sarah von Spiczak^{*§}

Ulrich Stephani*

Michael Siniatchkin[¶]

*Department of Neuropediatrics,
Christian-Albrechts-University, Kiel, Germany;

[†]Department of Neurology,
Christian-Albrechts-University, Kiel, Germany;

[‡]Department Biomedical Statistics and Multimodal Signal
Processing Unit, Johannes Gutenberg-University Mainz,
Klinik und Poliklinik für Neurologie Germany, Mainz
Department of Neurology, Germany, Mainz, Germany;

[§]Northern German Epilepsy Center for Children &
Adolescents, Schwentimental/OT Raisdorf, Germany; and

[¶]Department of Medical Psychology and Medical
Sociology, Christian-Albrechts-University, Kiel, Germany

REFERENCES

1. Japaridze N, Muthuraman M, Dierck C, et al. Neuronal networks in epileptic encephalopathies with CSWS. *Epilepsia* 2016;57:1245–1255.
2. Hegyi M, Siegler Z, Fogarasi A, et al. Age dependent features of lesional and non-lesional patients with Electrical Status Epilepticus in slow Sleep. *Ideggyogy Sz* 2014;30:69S.
3. Halász P, Hegyi M, Siegler Z, et al. Encephalopathy with Electrical Status Epilepticus in Slow Wave Sleep – a review with an emphasis on regional (perisylvian) aspects. *J Epileptol* 2014;22:71–87.
4. Loddenkemper T, Fernandez IS, Peters JM. Continuous spike and waves during sleep and electrical status epilepticus in sleep. *J Clin Neurophysiol* 2011;28:154–164.
5. Fernandez IS, Peters JM, Hadjiloizou S, et al. Clinical staging and electroencephalographic evolution of continuous spikes and waves during sleep. *Epilepsia* 2012;53:1185–1195.

6. Liukkonen E, Kantola-Sorsa E, Paetau R, et al. Long-term outcome of 32 children with encephalopathy with status epilepticus during sleep, or ESES syndrome. *Epilepsia* 2010;51:2023–2032.
7. Kramer U, Sagi L, Goldberg-Stern H, et al. Clinical spectrum and medical treatment of children with electrical status epilepticus in sleep (ESES). *Epilepsia* 2009;50:1517–1524.
8. Lawrence A, Nicholls SK, Stansfield SH, et al. Characterization of the tail-specific protease (Tsp) from *Legionella*. *J Gen Appl Microbiol* 2014;60:95–100.

The new ILAE seizure classification: 63 seizure types?

Dear Editors,

We have read with great interest the ILAE position papers on the new seizure classification.^{1,2} The papers nicely describe the reasoning behind the proposed new terminology of seizure types. However, not all names generated by the proposed algorithm are mentioned in the text. A detailed list with the names of all seizure types is necessary for standardization of nomenclature and communication between centers. To prevent the potential confusion

generated by translation into other languages, codes attributed to each seizure type would be helpful. This became obvious when we attempted to implement the new ILAE seizure classification into the revised version of SCORE (Standardized Computer-based Organized reporting of EEG [electroencephalography])³ by a taskforce of the International Federation of Clinical Neurophysiology, comprising 39 experts. Using the reasoning described in the ILAE position papers, we propose such a list, containing 63 seizure types (Table 1).

The other practical question concerns negative myoclonus. This is not mentioned in the new classification. We were wondering what the reason could be: (1) The authors do not consider that there is evidence for such a seizure type, although several studies indicated its existence and that its correct diagnosis can have therapeutic implications^{4–8}; (2) it should be described under myoclonic seizure types, adding “negative” in free text, as a descriptor; (3) it should be described as an atonic seizure—of very short duration. In the “Instruction manual,”² it is stated that wherever possible, prior accepted definitions from the ILAE Glossary of 2001⁹ were maintained, in order to support continuity of usage. Terms no longer recommended

Table 1. List of seizure types according to the new ILAE seizure classification

Three-step classification		Name of seizure type		Code
Focal onset	Aware	Motor onset—not further specified	Focal aware motor-onset seizure	I.A.01
		Myoclonic	Focal aware myoclonic seizure	I.A.02
		Clonic	Focal aware clonic seizure	I.A.03
		Tonic	Focal aware tonic seizure	I.A.04
		Atonic	Focal aware atonic seizure	I.A.05
		Automatisms	Focal aware automatism seizure	I.A.06
		Hyperkinetic	Focal aware hyperkinetic seizure	I.A.07
		Nonmotor onset—not further specified	Focal aware nonmotor onset seizure	I.A.08
		Behavior arrest	Focal aware behavior arrest seizure	I.A.09
		Sensory	Focal aware sensory seizure	I.A.10
		Emotional	Focal aware emotional seizure	I.A.11
		Cognitive	Focal aware cognitive seizure	I.A.12
		Autonomic	Focal aware autonomic seizure	I.A.13
		Onset not further specified	Focal aware seizure	I.A.14
Impaired awareness		Motor onset—not further specified	Focal impaired awareness motor onset seizure	I.B.01
		Myoclonic	Focal impaired awareness myoclonic seizure	I.B.02
		Clonic	Focal impaired awareness clonic seizure	I.B.03
		Tonic	Focal impaired awareness tonic seizure	I.B.04
		Atonic	Focal impaired awareness atonic seizure	I.B.05
		Automatisms	Focal impaired awareness automatism seizure	I.B.06
		Hyperkinetic	Focal impaired awareness hyperkinetic seizure	I.B.07
		Nonmotor onset—not further specified	Focal impaired awareness nonmotor onset seizure	I.B.08
		Behavior arrest	Focal impaired awareness behavior arrest seizure	I.B.09
		Sensory	Focal impaired awareness sensory seizure	I.B.10
		Emotional	Focal impaired awareness emotional seizure	I.B.11
		Cognitive	Focal impaired awareness cognitive seizure	I.B.12
		Autonomic	Focal impaired awareness autonomic seizure	I.B.13
		Onset not further specified	Focal impaired awareness seizure	I.B.14

Continued

GRAY MATTERS

Table 1. Continued.

Three-step classification		Name of seizure type	Code
Generalized Onset	Awareness not known or not specified	Motor onset—not further specified	I.C.01
		Myoclonic	I.C.02
		Clonic	I.C.03
		Epileptic spasms	I.C.04
		Tonic	I.C.05
		Atonic	I.C.06
		Automatisms	I.C.07
		Hyperkinetic	I.C.08
		Nonmotor onset—not further specified	I.C.09
		Behavior arrest	I.C.10
		Sensory	I.C.11
		Emotional	I.C.12
		Cognitive	I.C.13
		Autonomic	I.C.14
		Onset not further specified	I.C.15
Generalized Onset	Motor	Focal to bilateral tonic-clonic	I.D.01
		Onset not further specified	II.A.01
		Myoclonic	II.A.02
		Myoclonic-atonic	II.A.04
		Myoclonic-tonic-clonic	II.A.04
		Clonic	II.A.05
		Epileptic spasm	II.A.06
		Tonic	II.A.07
		Atonic	II.A.08
		Tonic-clonic	II.A.09
	Absence	Typical	II.B.01
		Atypical	II.B.02
		Myoclonic absence	II.B.03
		Eyelid myoclonia	II.B.04
Unknown onset	Motor	Tonic-clonic	III.A.01
		Epileptic spasm	III.A.02
		Motor—not further specified	III.A.03
	Nonmotor	Behavior arrest	III.B.01
		Nonmotor—not further specified	III.B.02
	Unknown	Unclassified seizure	III.C.01

for use are omitted. The 2001 Glossary⁹ recognized negative myoclonus as a specific seizure type, distinct from (positive) myoclonus, and this clinical entity is commonly used in clinical practice. Therefore, it would be important to highlight its placement in the seizure classification.

DISCLOSURE

None of the authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Sándor Beniczky^{1,2}

sbz@filadelfia.dk

Guido Rubboli^{3,4}

Harald Aurlen^{5,6}

Lawrence J. Hirsch⁷

Eugen Trinka^{8,9}

Donald L. Schomer¹⁰

on behalf of the SCORE consortium

¹Department of Clinical Neurophysiology, Aarhus University, Aarhus, Denmark;

²Danish Epilepsy Center, Dianalund, Denmark;

³Department of Neurology, Danish Epilepsy Center, Dianalund, Denmark;

⁴University of Copenhagen, Copenhagen, Denmark;

⁵Department of Neurology, Haukeland University Hospital, Bergen, Norway;

⁶Department of Clinical Medicine, University of Bergen, Bergen, Norway;

⁷Comprehensive Epilepsy Center, Yale University School of Medicine, New Haven, Connecticut, U.S.A.;

⁸Department of Neurology, Christian Doppler Klinik, Paracelsus Medical University and Center for Cognitive Neuroscience Salzburg, Salzburg, Austria;

⁹Institute for Public Health, Medical Decision Making and HTA, UMIT, Hall in Tyrol, Austria; and

¹⁰Department of Neurology, Laboratory of Clinical Neurophysiology, Beth Israel Deaconess Medical Center, Harvard University, Boston, Massachusetts, U.S.A.

REFERENCES

1. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. *Epilepsia* 2017;58:522–530.
2. Fisher RS, Cross JH, D'Souza C, et al. Instruction manual for the ILAE 2017 operational classification of seizure types. *Epilepsia* 2017;58:531–542.
3. Beniczky S, Aurlen H, Brögger JC, et al. Standardized computer-based organized reporting of EEG: SCORE. *Epilepsia* 2013;54:1112–1124.
4. Tassinari CA. New perspectives in epileptology. In Japanese Epilepsy Association (Ed) *Trends in modern epileptology*. Tokyo: Proceedings of the International Public Seminar on Epileptology Tokyo: Japanese Epilepsy Association, 1981:42–59.
5. Guerrini R, Dravet C, Genton P, et al. Epileptic negative myoclonus. *Neurology* 1993;43:1078–1083.
6. Tassinari CA, Rubboli G, Parmeggiani L, et al. Epileptic negative myoclonus. *Adv Neurol* 1995;67:181–197.
7. Oguni H, Uehara T, Tanaka T, et al. Dramatic effect of ethosuximide on epileptic negative myoclonus: implications for the neurophysiological mechanism. *Neuropediatrics* 1998;29:29–34.
8. Rubboli G, Mai R, Meletti S, et al. Negative myoclonus induced by cortical electrical stimulation in epileptic patients. *Brain* 2006;129:65–81.
9. Blumer WT, Luders HO, Mizrahi E, et al. Glossary of descriptive terminology for Ictal semiology: report of the ILAE task force on classification and terminology. *Epilepsia* 2001;42:1212–1218.

Response to the numbering of seizure types

To the Editors:

We thank the authors for their kind attention to the 2017 ILAE seizure type classification. Our target audience comprised general clinicians, patients with epilepsy, and the public (for the basic classification) and neurologists, epileptologists, and researchers (for the expanded classification). To keep the classification usable for this audience, the Classification Task Force chose to abbreviate only the most important seizure types, for example, FAS for focal aware seizure and FIAS for focal impaired awareness seizure. We have no objection to the suggested numbering system for use by specialized groups using the computerized SCORE system.

The question of negative myoclonus was not discussed extensively by our Task Force. The 2017 classification is not comprehensive and it omits mention of a number of seizure types. The distinction of negative myoclonus seizures from focal or generalized atonic seizures can be difficult. Diagnosis is confounded by nonepileptic negative myoclonus in the form of asterix. Despite these diagnostic issues, it would be acceptable to indicate that myoclonic seizures can have either positive or negative manifestations. Future research about this entity may clarify where negative myoclonus best fits into a classification.

DISCLOSURES OF CONFLICT OF INTEREST

Dr. Fisher has stock options from Avails Pharmaceuticals, Cerebral Therapeutics, Applied Neurometrics, Zeto, and SmartMonitor, and research grants from Medtronic. J. A. French discloses support via The Epilepsy Study Consortium, which pays Dr French's university employer for her consultant time related to Acorda, Alexza, Anavex, BioPharm Solutions, Concert, Eisai, Georgia Regents University, GW Pharma, Marathon, Marinus, Neurelis, Novartis, Pfizer, Pfizer-Neusentis, Pronutria, Roivant, Sage, SciFluor, SK Life Sciences, Takeda, Turing, UCB Inc., Ultragenyx, Upsher Smith, Xenon Pharmaceuticals, Zynerba grants, and research from Acorda, Alexza, LCGH, Eisai Medical Research, Lundbeck, Pfizer, SK life sciences, UCB, Upsher-Smith, Vertex, grants from NINDS, Epilepsy Therapy Project, Epilepsy Research Foundation, and the Epilepsy Study Consortium. She is on the editorial board of *Lancet Neurology*, *Neurology Today* and *Epileptic Disorders*, and was an Associate Editor of *Epilepsia*, for which she received a fee. Dr. Moshé receives from Elsevier annual compensation for his work as Associate Editor in Neurobiology of Disease and royalties from two books he co-edited. He received a consultant's fee from Lundbeck, Eisai, and UCB. The remaining authors listed no disclosures relevant to the classification of seizure types. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Robert S. Fisher¹

robert.fisher@stanford.edu

J. Helen Cross²

Carol D'Souza³

Jacqueline A. French⁴

Sheryl Haut⁵

Norimichi Higurashi⁶

Edouard Hirsch⁷

Floor E. Jansen⁸

Lieven Lagae⁹

Solomon L. Moshe¹⁰

Saul R. Korey¹¹

Dominick P. Purpura¹²

Jukka Peltola¹³

Eliane Roulet Perez¹⁴

Ingrid E. Scheffer¹⁵

Andreas Schulze-Bonhage¹⁶

Ernest Somerville¹⁷

Michael Sperling¹⁸

Elza Marcia Yacubian¹⁹

Sameer M. Zuberi²⁰

¹Stanford Department of Neurology and Neurological Sciences, Stanford University Medical Center, Stanford, California, U.S.A.;

²UCL-Institute of Child Health, Great Ormond Street, Hospital for Children, London, United Kingdom;

³Bombay Epilepsy Society, Mumbai, India;

⁴Department of Neurology, NYU Langone School of Medicine, New York, New York, U.S.A.;

⁵Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, U.S.A.;

⁶Department of Pediatrics, Jikei University School of Medicine, Tokyo, Japan;

⁷Unite Francis Rohmer, Strasbourg, France;

⁸Department of Pediatric Neurology, Brain Center Rudolf Magnus, University Medical Center, Utrecht, the Netherlands;

⁹Pediatric Neurology, University Hospitals KU Leuven, Leuven, Belgium;

¹⁰Department of Neurology;

¹¹Department of Pediatrics;

¹²Department Neuroscience, Montefiore Medical Center, Bronx, New York, U.S.A.;

¹³Department of Neurology, Tampere University Hospital, Tampere, Finland;

¹⁴Neurologie et Neurorehabilitation Pédiatrique, CHUV, Lausanne, Switzerland;

¹⁵Florey Institute and University of Melbourne, Austin Health and Royal Children's Hospital, Melbourne, Victoria, Australia;

¹⁶Epilepsy Center, University Medical Center Freiburg, Freiburg, Germany;

¹⁷Faculty of Medicine, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia;

¹⁸Department of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, Pennsylvania, U.S.A.;

¹⁹Department of Neurology and Neurosurgery, Unidade de Pesquisa e Tratamento das Epilepsias, São Paulo, Brazil; and

²⁰Paediatric Neurosciences Research Group, Royal Hospital for Children, Glasgow, United Kingdom

Novel *SMC1A* variant and epilepsy of infancy with migrating focal seizures: Expansion of the phenotype

To the Editors:

Symonds et al.¹ recently reported 10 females with frameshift or splice-site variants in Structural Maintenance Of Chromosomes 1A (*SMC1A*) with acquired microcephaly, severe developmental delay, cardiac malformations, and drug-resistant epilepsy, with a new association of seizure clustering. Herein, we report two further female infants, with novel de novo pathogenic variants in *SMC1A*, one of whom had epilepsy of infancy with migrating focal seizures (EIMFS), a phenotype not previously described in association with this gene.

Female one was born full term, the second child of nonconsanguineous Irish parents. Antenatal and birth course were uneventful. Early developmental milestones were achieved. She presented at 7 weeks with clusters of focal seizures that responded to phenobarbital and clon-

azepam. Aged 17 weeks, during a febrile illness, focal seizures with apnea emerged with associated developmental regression. Seizures were refractory to multiple therapies (carbamazepine, valproate, topiramate, pyridoxal-5-phosphate, phenytoin, and ketogenic diet) until she died at age 9 months. At 8 months, she had no head control, visual fixation, or vocalization, and there was acquired microcephaly (occipitofrontal circumference (OFC) 50th percentile to 0.4th percentile over 8 months) and profound axial hypotonia. She was nondysmorphic. Electroencephalography (EEG) was normal at age 7 weeks, and at 5 months showed a slow asymmetric background (left slower than right). At age 8 months, EEG showed features of EIMFS. Multiple focal seizures arose in the left hemisphere with simultaneous and sequential independent seizures arising from the right. Interictal EEG showed multifocal spike and poly-spike bursts and persistent background slowing. Trio whole exome sequencing identified a novel de novo heterozygous c.1114delG resulting in a premature stop codon (pVal372*) in *SMC1A* (GRCh39/hg17, NM_006306.3). The deleted nucleotide is in an acceptor splice site and is predicted to influence non-sense-mediated messenger RNA (mRNA) decay. Further details, including previous neurometabolic and genetic investigation, and post-mortem neuropathology findings are previously outlined (patient 12 of McTague et al.).²

The second female identified had a de novo splice-site variant in *SMC1A* (g.10734G>A) with a phenotype similar to those reported by Symonds et al.¹ She presented with clusters of focal seizures (7 weeks of age) and later developed clusters of tonic seizures (4 months), infantile spasms (9 months), and rare generalized tonic-clonic seizures (13 months). Treatment with multiples antiepileptic drugs and ketogenic diet had no sustained effect on the frequency of seizure clusters. Other features included antenatal and postnatal microcephaly (OFC 0.4th percentile), dysmorphic features (small hands and feet, incomplete single palmar creases, big hallux bilaterally extended), atrial septal defect, severe developmental delay, and profound hypotonia. She died at age 3 years. Multiple EEG studies demonstrated a slow background with frequent epileptiform discharges, maximally left temporal.

In our cohort of Irish patients with unexplained early onset epileptic encephalopathy (EOEE), loss of function variants in *SMC1A* were identified in two cases accounting for 2.7% of this population (and 5% of females), indicating that *SMC1A* encephalopathy may be an underrecognized diagnosis in females with EOEE. The identification of a loss-of-function variant in *SMC1A* in EIMFS expands the phenotype, number of genes, and mechanisms contributing to this devastating electroclinical syndrome.

DISCLOSURE

The authors have indicated they have no potential conflicts of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Kathleen M. Gorman¹
Kathleen.gorman@cuh.ie

Eva Forman¹

Judith Conroy²

Nicholas M. Allen³

Amre Shahwan¹

Sally A. Lynch^{2,4}

Sean Ennis²

Mary D. King^{1,2}

¹Department of Paediatric Neurology and Clinical Neurophysiology, Children's University Hospital, Dublin, Ireland;

²Academic Centre on Rare Diseases, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland;

³Department of Paediatrics, National University of Ireland Galway and Galway University Hospital, Galway, Ireland; and

⁴Department of Clinical Genetics, Children's University Hospital, Dublin, Ireland

REFERENCES

1. Symonds JD, Joss S, Metcalfe KA, et al. Heterozygous truncation mutations of the *SMC1A* gene cause a severe early onset epilepsy with cluster seizures in females: detailed phenotyping of 10 new cases. *Epilepsia* 2017;58:565–575.
2. McTague A, Appleton R, Avula S, et al. Migrating partial seizures of infancy: expansion of the electroclinical, radiological and pathological disease spectrum. *Brain* 2013;136:1578–1591.

ANNOUNCEMENTS

32nd International Epilepsy Congress

2–6 September 2017

Barcelona, Spain

Congress website: www.epilepsybarcelona2017.org

Upcoming Chapter Congresses

International Symposium on Status Epilepticus (ISSE2017 and 9th NEC)

17–19 July 2017

Cebu, Philippines

Announcement | Website: <http://www.isse2017.org/>

Journées française de l'Epilepsie (JFE)

9–12 October 2017

Palais du Pharo, Marseille, France

Organized by La Ligue Française contre l'Epilepsie (LFCE)

Website: <http://www.jfe-congres.fr/>

2017 CLAE Scientific Meeting

13–15 October 2017

Vancouver, BC, Canada

Website: <https://canadianleagueagainstepilepsy.wildapricot.org/2017-Meeting>

Other Congresses

Advanced International Course: Bridging Basic with Clinical Epileptology – 6

17–28 July 2017

San Servolo (Venice), Italy

Course Directors: Giuliano Avanzini and Marco de Curtis
Information

7th International Summer School for Neuropathology and Epilepsy Surgery (INES 2017)

22–25 July 2017

State University of Campinas – UNICAMP, Brazil
Flyer

11th Baltic Sea Summer School on Epilepsy (BSSSE 11)

6–11 August 2017

Tartu, Estonia

Clinically oriented, and focused on comprehensive aspects of diagnosis and treatment of epilepsy.

Announcement: Program, fees, and more information | Past BSSSE Schools | Website: www.epilepsiestiftung-wolf.de

XIV Workshop on Neurobiology of Epilepsy (WONOEP) 2017

28 August–1 September, 2017

Mon St Benet, Barcelona, Spain

Announcement | WONOEP Report

GRAY MATTERS

Eighth Caucasian Regional School of Clinical Epileptology (CRSSCE-VIII)

13–18 September 2017
Dilijan, Armenia

XIII World Congress of Neurology

16–21 September 2017
Kyoto, Japan
Website: www.2017.wcn-neurology.com/

Cleveland Clinic Epilepsy Update & Review Course

23–25 September 2017
InterContinental Hotel & Bank of America Conference
Center, Cleveland, Ohio, USA
Program | Website – Register by August 15 and save!

3rd International Epilepsy Symposium: New Insights into Epilepsy

29 – 30 September 2017
Berlin, Germany More information

ISPN 2017, 45th Annual Meeting of the International Society for Pediatric Neurosurgery

8–12 October 2017
Denver, Colorado, U.S.A.
Early Registration Deadline 14 August 2017
ISPNMeeting.org
12–14 October 2017
International Workshop on Onchocerciasis-Associated
Epilepsy (OAE)

ANA 2017: American Neurological Association Annual Meeting

15–17 October 2017
San Diego, CA, U.S.A.
Website

7th Eilat International Educational Course: Pharmacological Treatment of Epilepsy

15–20 October 2017
Jerusalem, Israel
Website: www.eilatedu2017.com – Course and bursary
information, applications

4th European Congress of NeuroRehabilitation (ECNR)

25–28 October 2017
SwissTech Convention Center, Lausanne, Switzerland
www.ecnr-congress.org

2nd Moroccan Congress of Neurophysiology

26–28 October
The First African and Middle Eastern Seminar of Clinical
Neurophysiology and Movement Disorders Confer-
ence Center Mohammed VI, Rabat City, Morocco
Website: Speakers, program, registration

2018 Congresses

12th World Congress on Controversies in Neurology (CONy)

22–25 March 2018
Warsaw, Poland
CONy 2018 Website

2nd International Training Course on Neuropsychology in Epilepsy

15–20 April 2018
Domaine de Châteauneuf, Provence, France Information

31st International Congress of Clinical Neurophysiology (ICCN) of the International Federation of Clinical Neurophysiology (IFCN)

1–6 May 2018
Washington, DC, U.S.A.
ICCN 2018 Website: <http://iccn2018.acns.org/>

GRAY MATTERS

4th International Congress on Brain and Mind

3–5 May 2018
Brno, Czech Republic
Read about the previous Brain and Mind congress

12th Asian and Oceanian Epilepsy Congress

21–24 June 2018
Bali, Indonesia
Website: www.epilepsybali2018.org

Regional Congresses

13th European Congress on Epileptology

26–28 August 2018
Vienna, Austria
website: www.epilepsyvienna2018.org

6th Global Symposium on Ketogenic Therapies for Neurological Disorders

5–8 October 2018
Embracing Diversity, Global Implementation and Individualized Care
International Convention Center Jeju, Jeju, Korea
Website: www.ketoconnect.org